drugset / Trial / NCT00874523
Raltegravir and Atazanavir Dosing Strategy Study
RandomizedCrossoverOpen-labelTreatment
Summary
To compare the steady-state pharmacokinetics and short-term efficacy and safety of two dosing strategies of raltegravir and atazanavir in virologically suppressed HIV-infected adults receiving atazanavir-containing combination antiretroviral therapy.
Timeline
- Start
- 2009-07
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atazanavir | Other / unclassified | 300 mg | — |
| Comparator | Raltegravir | Other / unclassified | 400 mg | — |
| Comparator | Raltegravir | Other / unclassified | 800 mg | — |
| Comparator | Ritonavir | Other / unclassified | 100 mg | — |